Clinical trial
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
NCT00027586 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00027586 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Metastatic Melanoma |
| Official title | Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Skin Neoplasms |
| Intervention type | Drug |
| Interventions | Imatinib mesylate (STI571) |
| Enrollment | 22 |
| Start date | Sep 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: